Fmr LLC Has $1.65 Million Stock Position in LivaNova PLC (NASDAQ:LIVN)

FMR LLC raised its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 68.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,466 shares of the company's stock after acquiring an additional 12,735 shares during the quarter. FMR LLC owned approximately 0.06% of LivaNova worth $1,653,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Driehaus Capital Management LLC raised its holdings in shares of LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company's stock worth $29,824,000 after purchasing an additional 213,749 shares during the period. Perceptive Advisors LLC boosted its stake in LivaNova by 48.5% during the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company's stock valued at $24,340,000 after acquiring an additional 145,000 shares during the last quarter. Great Lakes Advisors LLC bought a new stake in LivaNova in the second quarter valued at about $16,614,000. Cornercap Investment Counsel Inc. bought a new stake in shares of LivaNova in the 2nd quarter valued at approximately $1,103,000. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of LivaNova by 3.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company's stock worth $41,889,000 after buying an additional 25,277 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

LIVN has been the topic of several recent research reports. Robert W. Baird lifted their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. Baird R W raised shares of LivaNova from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 17th. The Goldman Sachs Group began coverage on LivaNova in a report on Friday, October 4th. They issued a "buy" rating and a $65.00 target price on the stock. StockNews.com downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Saturday, November 16th. Finally, Needham & Company LLC restated a "buy" rating and set a $75.00 price objective on shares of LivaNova in a research report on Monday, November 25th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $69.17.

LivaNova Stock Down 2.6 %

LIVN stock traded down $1.35 during midday trading on Monday, hitting $50.15. The company's stock had a trading volume of 520,963 shares, compared to its average volume of 609,696. LivaNova PLC has a twelve month low of $43.15 and a twelve month high of $64.47. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company's fifty day moving average price is $51.97 and its 200 day moving average price is $51.43. The stock has a market capitalization of $2.72 billion, a P/E ratio of 122.62 and a beta of 0.98.

Insider Activity at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares of the company's stock, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.27% of the stock is currently owned by corporate insiders.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.